目錄
1 Outlook of the Antiviral Drug Era, Now More Than 50 Years After Description of the First Antiviral Drug (Erik De Clercq).
2 Inhibition of HIV Entry (José A. Esté).
3 Targeting Integration Beyond Strand Transfer: Development of Second-Generation HIV Integrase Inhibitors (Arnout R.D. Voet, Marc De Maeyer, Frauke Christ, and Zeger Debyser).
4 From Saquinavir to Darunavir: The Impact of 10 Years of Medicinal Chemistry on a Lethal Disease (Marie-Pierre de Béthune, Anik Peeters, and Piet Wigerinck).
5 Acyclic and Cyclic Nucleoside Phosphonates (Richard L. Mackman and Tomas Cihlar).
6 Helicase–Primase Inhibitors: A New Approach to Combat Herpes Simplex Virus and Varicella Zoster Virus (Subhajit Biswas and Hugh J. Field).
7 Cyclophilin Inhibitors (Grégoire Vuagniaux, Arnaud Hamel, Rafael Crabbé, Hervé C. Porchet, and Jean-Maurice Dumont).
8 Alkoxyalkyl Ester Prodrugs of Antiviral Nucleoside Phosphates and Phosphonates (James R. Beadle and Karl Y. Hostetler).
9 Maribavir: A Novel Benzimidazole Ribonucleoside for the Prevention and Treatment of Cytomegalovirus Diseases (Karen K. Biron).
10 Anti-HCMV Compounds (Graciela Andrei and Robert Snoeck).
11 Lethal Mutagenesis as an Unconventional Approach to Combat HIV (Pinar Iyidogan and Karen S. Anderson).
12 Recent Progress in the Development of HCV Protease Inhibitors (Nagraj Mani, Bhisetti G. Rao, Tara L. Kieffer, and Ann D. Kwong).
13 Antiviral RNAi: How to Silence Viruses (Karin J. von Eije and Ben Berkhout).
14 Neuraminidase Inhibitors as Anti-Influenza Agents (Willard Lew, Michael Z. Wang, Xiaowu Chen, James F. Rooney, and Choung Kim).
15 From TIBO to Rilpivirine: The Chronicle of the Discovery of the Ideal Nonnucleoside Reverse Transcriptase Inhibitor (Erik De Clercq).
References.
Index. |